Abstract

Insmed Incorporated is scheduled to report first-quarter 2026 results on May 7, 2026 Pre-Market, with current forecasts pointing to revenue of 301.54 million US dollars year over year growth of 227.48%, an adjusted EPS near -0.97, and investor attention centered on Brinsupri launch traction and the Arikayce label expansion path.

Market Forecast

The prevailing forecast for the current quarter anticipates revenue of 301.54 million US dollars, up 227.48% year over year, alongside an adjusted EPS estimate of -0.97, implying a 27.55% year over year improvement; EBIT is projected at -196.94 million US dollars, an approximate 15.52% year over year improvement in operating loss. Forecasts do not consistently include margin assumptions, and consensus modeling remains focused on the trajectory of the new revenue contribution and the cadence of operating expenses. The core commercial portfolio is expected to extend sequential growth as prescriber adoption broadens and refill patterns mature, while management commentary is likely to frame sustainability of demand and near-term access dynamics as the primary variables to watch. Analysts identify Brinsupri (brensocatib) as the largest growth driver this quarter, with modeled revenue around 201.30–209.00 million US dollars; year-over-year comparison is not meaningful given the limited base a year ago.

Last Quarter Review

In the prior quarter, Insmed Incorporated delivered revenue of 263.84 million US dollars, up 152.62% year over year, with a gross profit margin of 83.24%, a GAAP net loss attributable to common shareholders of 328.00 million US dollars, a net profit margin of -124.50%, and an adjusted EPS of -1.54, down 16.67% year over year. A key financial takeaway was the scale-up of operating spending to support commercial and development priorities, reflected in EBIT of -319.75 million US dollars, while top-line momentum continued to strengthen into year-end. The company’s commercial therapies collectively generated 263.84 million US dollars in the quarter, advancing 152.62% year over year, underscoring the early contribution from new launches and the resiliency of the established product base.

Current Quarter Outlook

Main business: commercial revenue, margins, and operating cadence

The central question for this quarter is the cadence of commercial revenue as adoption deepens. The revenue estimate of 301.54 million US dollars implies a sequential lift from 263.84 million US dollars last quarter, largely driven by the ramp of Brinsupri combined with steady base demand for the established product. Given the last quarter’s gross profit margin of 83.24%, investors will parse management’s comments for any changes in product mix, co-pay dynamics, and manufacturing costs that could shift margin mix in the near term. Gross margin forecasting is sparse in the market’s models for Q1, but the prior-quarter level provides a useful anchor to interpret incremental changes once reported.

Operating expenses remain another defining swing factor for the quarter’s EPS and EBIT prints. The current EPS estimate near -0.97 and EBIT forecast of -196.94 million US dollars both embed expectations of disciplined spending even as commercialization investments continue. The magnitude of year over year growth in revenue (227.48% on the forecast) mechanically improves operating leverage, yet actual leverage will depend on how rapidly field force and patient support costs scale relative to the pace of net sales. Commentary around field productivity, patient on-therapy persistence, and claims adjudication cycle times will therefore be closely followed to contextualize spending efficiency.

Beyond the headline metrics, qualitative color on payer interactions and refill dynamics will shape how the Street extrapolates the next few quarters. Positive refill trends support the notion that the initial wave of prescriptions is translating to longer-duration therapy, which can reduce revenue volatility and improve visibility. Conversely, any suggestion of pushback on access or higher-than-expected discontinuation would tilt sentiment toward more conservative run-rate assumptions. Taken together, a revenue print in line with or above 301.54 million US dollars, accompanied by commentary indicating sustained adoption and controlled spend, would align with the expected improvement in adjusted EPS and EBIT embedded in consensus.

Most promising business: Brinsupri (brensocatib) launch trajectory

Brinsupri is widely modeled as the principal driver of quarter-on-quarter growth. Survey-based work cited by several sell-side institutions points to broadening prescriber penetration and a rising share of eligible patients initiating therapy. Recent analyst models place first-quarter Brinsupri revenue in the ballpark of 201.30–209.00 million US dollars, which would account for a substantial portion of total revenue if achieved. Although year over year comparisons are not meaningful given the nascent base a year ago, the sequential step-up implied by these models offers a clear lens to gauge adoption velocity.

The key operational indicators that will help validate or challenge these revenue ranges include new patient starts, refill rates, and net-to-gross dynamics. Early adoption can sometimes be front-loaded with pent-up demand, so the Street will look for signs that new starts remain robust even as refill cohorts expand. Net-to-gross adjustments can be fluid during launch phases as co-pay assistance, distribution fees, and patient support programs scale; stable or improving net-to-gross would bolster confidence that reported revenue reflects durable demand rather than temporary program effects. Access trends are another focal point: reports suggesting manageable payer interactions set an expectation that prior authorization and coverage decisions will not materially impede growth in the near term.

A secondary dimension is prescriber breadth. Movement from concentrated high-prescriber clusters into a wider base of moderate prescribers supports a more durable trajectory. Commentary that indicates increasing geographic dispersion among writers, growing comfort with initiation criteria, and a favorable safety/tolerability profile in routine practice would reinforce the idea that Brinsupri’s ramp can extend through 2026 without pronounced saturation effects. Given that multiple institutions have published 2026 sales estimates above 1.00 billion US dollars, the reported Q1 mix of new and refill prescriptions—and any guidance or color on quarter-to-quarter seasonality—will likely drive revisions to second-quarter and full-year models.

Key stock-price drivers this quarter: Arikayce label expansion, R&D mix shift, and pipeline headlines

For the legacy commercial asset, the company recently disclosed positive Phase 3b data in a setting aligned with a broader patient population, and management has guided to pursue supplemental regulatory filings in the second half of the year. While these filings are not within the Q1 print, investors will watch for any operational updates that inform timing, scope, and potential commercial implications in key geographies. The degree to which Arikayce can add incremental growth via label expansion informs out-year revenue diversity and could modestly cushion volatility in the Brinsupri trajectory as the launch matures.

On the spending side, the prior quarter’s EBIT loss of -319.75 million US dollars provides a baseline for the level of investment committed to commercialization and development programs. The forecast improvement to a -196.94 million US dollars EBIT loss implies tangible operating leverage if revenue meets expectations. Management’s commentary on the allocation of selling, general, and administrative versus research and development expenses, as well as any one-time launch or study-related costs, will help the market discern whether the improvement is structural or transitory. Clarity here is significant for the near-term EPS path, given that consensus expects adjusted EPS to improve from -1.54 last quarter to approximately -0.97 in Q1.

Lastly, pipeline headlines can influence sentiment around revenue durability beyond the current commercial base. Earlier in April, the company discontinued development of brensocatib in hidradenitis suppurativa after a Phase 2b miss, removing a potential future indication. While this decision narrows optionality in one program, investors appear more focused on the pulmonary program potential that has been tracked since mid-2025 and on potential label actions around the established product. Any incremental disclosure on development timelines, study initiations, or regulatory interactions will frame expectations for 2026–2027 catalysts that, while outside this quarter’s financials, may influence valuation multiples applied to the commercial trajectory reported now.

Analyst Opinions

Bullish sentiment dominates recent research, with approximately eight Buy/Outperform ratings versus zero Sell ratings and two Hold/Neutral views in the latest wave of notes—effectively an 8:0 ratio of bullish to bearish opinions, with neutral commentary comprising the remainder. Multiple well-followed institutions emphasize the same core thesis: accelerating Brinsupri adoption, supportive prescriber and payer feedback, and incremental contributions from the established product base that together underpin a path to improving operating leverage through 2026.

RBC Capital Markets maintains an Outperform stance and recently highlighted favorable physician feedback on Brinsupri. RBC’s latest work points to manageable payer dynamics and a market structure in which moderate and high prescribers account for a significant share of early volume, supporting the momentum needed for a steady ramp. RBC frames first-quarter Brinsupri revenue around 201.30 million US dollars and sees 2026 sales near 1.35 billion US dollars. The survey-based signal—positive prescriber experience in routine practice—underpins RBC’s confidence that early demand is translating into repeat prescribing rather than one-time trial usage. The bank’s price target increases through April reflect this combination of favorable field insights and the potential for label expansion to add incremental contributions beyond the launch product.

Morgan Stanley’s coverage corroborates the bullish adoption narrative. In late March, the team upgraded the shares to Overweight and raised its price target to 212.00 US dollars while citing survey results indicating that a large majority of pulmonologists have already prescribed Brinsupri, with patient share expected to climb through year-end. Morgan Stanley models approximately 209.00 million US dollars in first-quarter Brinsupri sales and highlights refill dynamics and low discontinuation rates as indicators of durability. In their analysis, a growing base of repeat prescriptions materially improves revenue visibility for 2026 and 2027, and with it the prospect of operating leverage as launch support costs normalize relative to cumulative net sales.

Other institutions cluster around similar themes. Wells Fargo reiterates a Buy rating with a target of 177.00 US dollars, focusing on the scaling commercial contribution and the improving balance between top-line expansion and opex intensity. Barclays maintains a Buy with a 237.00 US dollars target, pointing to execution in launch logistics and patient support infrastructure that typically precede steadier refill cohorts. Bank of America Securities remains positive with a 211.00 US dollars target, and Jefferies likewise signals a Buy with a 230.00 US dollars objective; both highlight the path to multi-quarter adoption and the potential for the established product’s label progress to diversify drivers. UBS and Mizuho, while adjusting targets within a constructive range, maintain Buy/Outperform ratings predicated on the same operational markers—new patient starts, payer access, and refill persistence—feeding into improving quarterly earnings quality.

The bullish case coalesces around a coherent set of measurable checkpoints for the current print. First, revenue at or above 301.54 million US dollars would align with Brinsupri revenue near the modeled 201.30–209.00 million US dollars band and signal that the refill base is scaling at least as quickly as previously expected. Second, confirmation that net-to-gross remains within planning ranges would reduce uncertainty around reported sales conversion and help analysts fine-tune gross-to-net assumptions for the remainder of 2026. Third, management detail on operating expenses—especially the balance of commercialization investment versus variable launch support outlays—will indicate whether the implied 15.52% year over year improvement in EBIT loss is sustainable. Finally, incremental clarity on the regulatory timetable for the legacy asset’s label expansion could nudge outer-year estimates upward, supporting the valuation framework that many of these institutions use to justify price targets above 200.00 US dollars.

What these views share is an emphasis on data points that translate directly into forward revisions: the number of prescribers writing the product, the persistence profile of patients already on therapy, and the friction—or lack thereof—in payer interactions that determine speed to first fill and adherence over time. Should the company’s commentary affirm that denials are not a major obstacle and that refill rates are consistent with or better than modeled expectations, buy-side models are likely to keep their revenue and EPS trajectories intact or even edge higher for the back half of 2026. Conversely, if net-to-gross trends or spending cadence differ materially from assumptions, EPS could deviate from the -0.97 estimate even if top-line meets expectations; that caveat is precisely why bullish analysts emphasize visibility into launch efficiency metrics as essential to near-term share performance.

In sum, the majority of analysts entering the print expect a top-line step-up to roughly 301.54 million US dollars, driven predominantly by Brinsupri, with operating metrics that point to improving EPS and EBIT on a year over year basis. The research community’s resonance around prescriber breadth, payer experience, and refill persistence provides a clear scorecard for assessing the quarter. If the company’s reported results and commentary align with these pillars, the bullish case—centered on robust commercial execution and improving operating leverage—would remain the prevailing interpretation among institutions ahead of midyear catalysts.